May 30, 2025 4:50pm

Sell in May and go away is over; however, equities experienced pressure from pension rebalance selling

Then, President Trump accused China of violating its preliminary trade deal with the U.S. as U.S. appeals court reinstates Trump tariffs

With a blessing as econs came in slightly below expectations, as the inflation rate slipped to 2.1% in April, lower than expected, Fed’s preferred gauge shows

News: Intellia Therapeutics (NTLA -$0.58 or -7.79% after Thursday’s -22.9%) after it announced an update from the ongoing P3 study, evaluating the investigational in vivo genome-editing candidate, nexiguran ziclumeran (nex-z), for treating ATTR amyloidosis with cardiomyopathy (ATTR-CM). 1 of the patients in the P3 MAGNITUDE study, which evaluated nex-z for treating ATTR-CM, experienced grade 4 liver transaminase elevations, indicating a notable increase in liver enzymes. The patient was asymptomatic and identified during laboratory tests. NTLA also noted that this adverse event appeared to resolve without hospitalization or medical interference.

Always be vigilant concerning your portfolio … why you need RMi!

Never leave an investor uninformed!  

On point, short on words, long on facts and being judicious!

My mission is to provide clear, actionable guidance on a regular basis to help investors and traders navigate the uncertain and often irrational financial markets.

I put hours of effort to create reporting, while leveraging my 40 years of operating. investigative and research experiences to analyze the key market-moving events and distill that into a cogent outlook.

 

Friday, RegMed Investors’ (RMi) pre-open: econs revisit … https://www.regmedinvestors.com/articles/13939

Thursday night’s RegMed Investors (RMi) Closing Bell: up. downs; I always thought were a military exercise and now a sector reality … https://www.regmedinvestors.com/articles/13938

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB: HRGN): No partner, No cash, NO runway, extensive liabilities and debts to past employee and university associations … https://www.regmedinvestors.com/articles/13812

 

Friday: The Dow closed UP +54.34 points or +0.13%, the S&P closed DOWN -0.48 points or -0.01% while the Nasdaq closed DOWN -62.11 points or -0.32%

  • Indexes closed the week and month of May - mixed
  • For the week, the S&P 500 advanced +1.5%, while the Dow is up +1% and the Nasdaq popped +1.9%.
  • For the month, the S&P 500 advanced +5%, while the Dow is up +3% and the Nasdaq popped +9.5%.

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies

  • The personal consumption expenditures price index came in at 2.1% for April on an annualized basis. That’s slightly below the 2.2% consensus forecast from economists.
  • The University of Michigan Surveys of Consumers showed a revised 52.2 reading on sentiment, flat from April but a bit better than the previous level in mid-month. The level nonetheless was down 24.5% from a year ago.
  • On inflation, the 1-year outlook stood at a still-elevated 6.6% that was down more than 1/2 a percentage point from the mid-month level. At the 5-year horizon, the outlook edged down to 4.2%, the 1st decline since December.

Friday’s advance/decline line opened with a negative 2 incliner, 32 decline and 1 flat ending with a negative close of 6 incliners, 26 decliners and 3 flats          

Metrics:  Friday, the IBB was down -2.52%, the XBI was down -1.27% while the VIX was down -0.53 points or -2.77% at 18.65

 

Q2/25 – May – 1 market holiday, 10 negative and 11 positive closes

  • April – 11 positive and 10 negative closes

Q1/25

  • March, 10 positive and 12 negative closes
  • February – 12 holiday, 11 negative and 7 positive closes
  • January - 2 holidays, 1 market close, 10 negative and 10 positive closes

 

Fridays Closing UP (6 of 6) 

  • Alnylam Pharmaceuticals (ALNY +$11.66 after Thursday’s +$7.34 after Wednesday’s -$4.54),
  • Agenus (AGEN +$0.23 after Thursday’s +$0.18, Wednesday’s -$0.53, Tuesday -$0.27 and Monday holiday),
  • Harvard Apparatus RT (OTCQB: HRGN +$0.05 after Thursday’s -0.05, Wednesday’s +0.185, Tuesday’s $0.00 and Monday’s $0.00),
  • Ionis Pharmaceuticals (IONS +$0.05 after Thursday’s +$1.03, Wednesday’s -$0.89, Tuesday +$0.34 and Monday holiday),
  • Cellectis SA (CLLS +$0.02),
  • Sangamo Therapeutics (SGMO +$0.0073),

Flat (3)

  • bluebird bio (BLUE),
  • Brainstorm Cell Therapeutics (BCLI),
  • Homology Medicine (FIXX)

Friday’s Closing DOWN (10 of 26): 

  • Blueprint Medicine (BPMC -$1.71 after Thursday +$7.76, Wednesday’s -$4.76 after Tuesday -$1.44 after Monday holiday)
  • Ultragenyx Pharmaceuticals (RARE -$1.00 after Thursday +$0.68, Wednesday’s -$0.73, Tuesday -$0.58 after Monday holiday),
  • Intellia Therapeutics (NTLA -$0.58 after Thursday -$2.21 after Wednesday +$0.34),
  • Beam Therapeutics (BEAM -$0.49 after Thursday -$0.56),
  • CRISPR Therapeutics (CRSP -$0.49 after Thursday -$0.44, Wednesday -$0.35, Tuesday’s +$0.71 and Monday holiday),
  • BioLife Solutions (BLFS -$0.44 after Thursday -$0.03, Wednesday’s +$0.09, Tuesday’s +$0.46 and Monday holiday),
  • uniQure NV (QURE -$0.43),
  • Moderna (MRNA -$0.37 after Thursday +$0.88, Wednesday’s -$0.71,Tuesday +$0.50 and Monday holiday),
  • Lenz Therapeutics (LENZ -$0.33 after Thursday +$0.82, Wednesday’s -$0.69, Tuesday +$1.23 and Monday's holiday),
  • Verve Therapeutics (VERV -$0.15 after Thursday’s +$0.36),

 

The BOTTOM LINE: The cell and gene therapy sector dived Friday after Thursday’s jive after diving on Wednesday, urged on Tuesday following Monday’s holiday.

Cell and gene therapy sector equities popped on Tuesday after Monday’s holiday …

  • After getting squashed last Friday after making a barely positive progress on Thursday, unfollowing Wednesday’ negative finish, Tuesday’s following Monday’s positive …

As of  Friday’s trading session, health care was the only sector in the S&P 500 pacing to end the month lower, last on track for a 5.8% decline.

  • Some of the sector’s other biggest decliners included Eli Lilly, Humana and Merck
  • Also, the small cap-focused Russell 2000 slipped 0.8% in Friday’s session

 

May ‘25 … is DONE!

  • 5/30 – Friday closed negative with 6 positive, 26 negative and 3 flats
  • 5/29 – Thursday closed positive with 24 positive, 10 negative and 1 flat
  • 5/28 – Wednesday’s closed negative with 7 positive, 26 negative and 2 flats
  • 5/27 – Tuesday closed positive with 21 positive, 11 negative and 3 flats
  • 5/26 – Monday market holiday
  • 5/23 – Friday closed negative with 7 positive, 25 negative and 3 flats
  • 5/22 – Thursday closed positive with 19 positive, 14 negative and 2 flats
  • 5/21 – Wednesday closed negative with 3 positive, 30 negative and 2 flats
  • 5/20 – Tuesday closed positive with 23 positive, 9 negative and 3 flats
  • 5/19 – Monday closed positive with 23 positive, 12 negative and 1 flat
  • 5/16 - Friday closed positive with 29 positive, 3 negative and 3 flats
  • 5/15 – Thursday closed positive with 24 positive, 10 negative and 1 flat
  • 5/14 – Wednesday closed negative with 8 positive, 25 negative and 2 flats
  • 5/13 – Tuesday closed negative with 6 positive, 28 negative and 1 flat
  • 5/12 - Monday positive with 39 positive, 3 negative and 2 flats
  • 5/9 - Friday closed negative with 10 positive, 23 negative and 2 flats
  • 5/8 – Thursday closed positive with 25 positive, 8 negative and 2 flats
  • 5/7 - Wednesday closed positive with 16 positive, 15 negative and 4 flats
  • 5/6 – Tuesday closed negative with 2 positive, 31 negative and 2 flats
  • 5/5 - Monday closed negative with 9 positive, 23 negative and 3 flats
  • 5/2 – Friday closed positive with 24 positive, 8 negative and 3 flats
  • 5/1 - Thursday closed negative with 14 positive, 19 negative and 2 flats

 

I usually write/say “electronic trading and uncle algo” slips in and out, back doors reaping sector disharmony and then pops right back for some profiteering.

  • What can I say, love ‘em, leave ‘em and welcome back to save the sector’s honor – “uncle algo and his electronic dwarfs.”
  • Algos and electronic trading, can’t do with them and can’t do without them <me>

“I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

  • If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.

 

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:   

  • Friday: Alnylam Pharmaceuticals (ALNY), Agenus (AGEN) and Harvard Apparatus RT (OTCQB: HRGN)
  • Thursday: Blueprint Medicine (BPMC), Alnylam Pharmaceuticals (ALNY) and Ionis Pharmaceuticals (IONS)
  • Wednesday: Intellia Therapeutics (NTLA), BioLife Solutions (BLFS) and Vericel (VCEL)
  • Tuesday: Lenz Therapeutics (LENZ), Vericel (VCEL) and CRISPR Therapeutics CRSP)
  • Monday: Holiday

The worst three (3) in the session: 

  • Friday: Blueprint Medicine (BPMC), Ultragenyx Pharmaceuticals (RARE) and Intellia Therapeutics (NTLA)
  • Thursday:  Intellia Therapeutics (NTLA), Vericel (VCEL) and CRISPR Therapeutics CRSP)
  • Wednesday: Blueprint Medicine (BPMC), Alnylam Pharmaceuticals (ALNY) and Ultragenyx Pharmaceuticals (RARE)
  • Tuesday: Regenxbio (RGNX), Blueprint Medicine (BPMC) and Ultragenyx Pharmaceuticals (RARE)
  • Monday: Holiday

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.